Earlier this week, Elizabeth Holmes did something unusual. The normally cryptic founder and C.E.O. of Theranos, the embattled blood-testing start-up once valued at $9 billion, presented data on the state of her company’s technology to the scientific community. And from appearances, members of the scientific community were eager to hear what she had to say. At the annual meeting of the American Association for Clinical Chemistry, in Philadelphia, Holmes addressed a room filled with some 2,500 people, not including two separate overflow rooms, where attendees watched her presentation via a live feed.
